Exploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma
Authors:
- Kenji HosoyaKHKenji Hosoya
- Sangho KimSKSangho Kim
- Ryohei KinoshitaRKRyohei Kinoshita
- Naoya MaekawaNMNaoya Maekawa
- Satoru KonnaiSKSatoru Konnai
- Satoshi TakagiSTSatoshi Takagi
- Michihito TagawaMTMichihito Tagawa
- Yumiko KagawaYKYumiko Kagawa
- Tatsuya DeguchiTDTatsuya Deguchi
- Ryo OwakiRORyo Owaki
- Yurika TachibanaYTYurika Tachibana
- Madoka YokokawaMYMadoka Yokokawa
Open Access
- 2 September 2025
- journal article
- research article
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (9) , 850
Abstract
Oral malignant melanoma (OMM) is a highly aggressive malignancy in dogs. The development of effective systemic therapies is urgently required to improve the treatment of canine OMM. Immunotherapy using immune checkpoint inhibitors (ICIs) has been investigated in canines following their dramatic success in human cancer treatment; however, there is still a need for extensive veterinary clinical studies to clarify and optimize their clinical benefits. Among the ICIs under development for canine cancer immunotherapy, c4G12 (HFC-L1), a canine chimeric anti-PD-L1 antibody, has shown promising efficacy in dogs with pulmonary metastatic OMM in previous clinical studies. However, the optimal dose of HFC-L1/c4G12 has not yet been determined. To explore the dose–response relationship of HFC-L1, a multicenter, randomized clinical study was conducted using three different doses (2, 5, or 10 mg/kg via intravenous infusion every 2 weeks) to treat dogs with pulmonary metastatic OMM (n = 8–9 per group). The safety profiles were similar among the dose groups, and numerically longer median overall survival was achieved in the higher dose groups (5 and 10 mg/kg) than in the 2 mg/kg group. Although the study was exploratory in nature with a small sample size, 5–10 mg/kg should be considered the preferred dose in future clinical studies using HFC-L1.Keywords
Funding Information
- Japan Society for the Promotion of Science (JSPS) (21K14983, 23K23768, 25K02162, 25K02163, JP223fa627005, JP25ama121008)
- Japan Agency for Medical Research and Development (AMED) (21K14983, 23K23768, 25K02162, 25K02163, JP223fa627005, JP25ama121008)
This publication has 31 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Canine Oral MelanomaClinical Techniques in Small Animal Practice, 2007
- Oral malignant melanoma – the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapyVeterinary and Comparative Oncology, 2005
- Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogsJournal of the American Veterinary Medical Association, 2004
- A Comparative Review of Melanocytic NeoplasmsVeterinary Pathology, 2002
- Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989–2000)Journal of the American Veterinary Medical Association, 2001
- Radiotherapy of oral malignant melanomas in dogsJournal of the American Veterinary Medical Association, 1996
- 0–7–21 Radiation Therapy for the Treatment of Canine Oral MelanomaJournal of Veterinary Internal Medicine, 1994
- Canine Oral Melanoma: Comparison of Surgery Versus Surgery Plus Corynebacterium parvumCancer Investigation, 1986